(Corrects dateline to Sept 2 from Sept 1)
Sept 2 Merck & Co Inc said it would
cease the development of its experimental osteoporosis drug
after an independent analysis confirmed that the therapy was
associated with an increased risk of stroke.
While the drug, odanacatib, reduces the risk of osteoporotic
fractures, the increased risk of stroke in a late-stage study in
postmenopausal women does not support regulatory approval, the
company said on Friday.
(Reporting by Natalie Grover in Bengaluru; Editing by Anil